Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 27;12(7):2525.
doi: 10.3390/jcm12072525.

Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) Add-On Therapy to a Standard Treatment in Individuals with Multiple Sclerosis and Concomitant Symptoms of Depression-Results from a Randomized Clinical Trial and Pilot Study

Mohammad Ahmadpanah  1   2 , Shiva Amini  2 , Mehrdokht Mazdeh  3 , Mohammad Haghighi  2 , Alireza Soltanian  4 , Leila Jahangard  2 , Amir Keshavarzi  2 , Serge Brand  5   6   7   8   9   10
Affiliations

Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) Add-On Therapy to a Standard Treatment in Individuals with Multiple Sclerosis and Concomitant Symptoms of Depression-Results from a Randomized Clinical Trial and Pilot Study

Mohammad Ahmadpanah et al. J Clin Med. .

Abstract

Background: Compared to the general population, persons with multiple sclerosis (MS) are at increased risk of suffering from major depressive disorder (MDD). Repetitive Transcranial Magnetic Stimulation (rTMS) was used successfully to treat individuals with MDD. Here, we conducted a randomized clinical trial and pilot study, and tested the effectiveness of rTMS adjuvant to a standard pharmacological treatment among persons with MS, compared to a sham condition.

Materials and methods: A total of 40 persons with MS (mean age: 32 years; 42.5% females; median EDSS score: 4) and with moderate to severe symptoms of depression were randomly assigned to the rTMS or to the rTMS sham condition, always as adjuvant intervention to the standard treatment with sertraline, a selective serotonin reuptake inhibitor (SSRI). rTMS consisted of 10 sessions each of 37.5 min; the sham condition was identical to the active condition except for the absence of rTMS stimuli. At the beginning and two weeks after the end of the study, participants reported on their fatigue, while experts rated the severity of participants' depressive symptoms (Montgomery-Asberg Depression Rating Scale; MADRS), cognitive performance (Montreal Cognitive Assessment; MoCA), and degree of disability (Expanded Disability Status Scale; EDSS).

Results: Data were analyzed per intent-to-treat. Scores for depression, fatigue, and EDSS declined significantly over time (large effect sizes), but more so in the rTMS condition than in the sham condition (large effect sizes for the time by group-interactions). Compared to the sham condition, scores for depression were significantly lower in the rTMS condition. Scores for cognition improved over time in both study conditions (large effect size).

Conclusion: Compared to a sham condition, adjuvant rTMS to a standard pharmacological treatment ameliorated typical MS-related symptoms (depression; fatigue; EDSS scores). Results from this pilot study suggested that rTMS might be routinely applied in persons with MS displaying symptoms of depression and fatigue.

Keywords: EDSS; depression; fatigue; multiple sclerosis; rTMS; sham condition.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow-chart reflecting the number of participants at each state of the study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dobson R., Giovannoni G. Multiple sclerosis—A review. Eur. J. Neurol. 2019;26:27–40. doi: 10.1111/ene.13819. - DOI - PubMed
    1. McGinley M.P., Goldschmidt C.H., Rae-Grant A.D. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325:765–779. doi: 10.1001/jama.2020.26858. - DOI - PubMed
    1. Kaminska J., Koper O.M., Piechal K., Kemona H. Multiple sclerosis—Etiology and diagnostic potential. Adv. Hyg. Exp. Med. 2017;71:551–563. doi: 10.5604/01.3001.0010.3836. - DOI - PubMed
    1. McKay K.A., Kwan V., Duggan T., Tremlett H. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: A systematic review. BioMed Res. Int. 2015;2015:817238. doi: 10.1155/2015/817238. - DOI - PMC - PubMed
    1. Nicholas R., Rashid W. Multiple sclerosis. Am. Fam. Physician. 2013;87:712–714. - PubMed

LinkOut - more resources